Amgen will pay an initial $55m and up to $666m in cash subject to milestones.
US-listed drugs group Amgen has agreed to acquire Rodeo Therapeutics, a US-based small-molecule therapy developer for tissue, for up to $721m. Amgen will pay an initial $55m and up to $666m in cash subject to milestones. In July 2017, Rodeo raised $5.9m in series A financing from investors including pharmaceutical firms AbbVie, Eli Lilly, Johnson & Johnson…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.